In conclusion, this study suggests that CCX282-B, an orally-administered and specific CCR9 antagonist, provides a novel approach to modulating intestine-specific inflammatory responses, and if results are confirmed might be an effective therapy for IBD. The gene discussed is CCR9; the disease is inflammatory bowel disease.